These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

269 related articles for article (PubMed ID: 24503695)

  • 1. Preclinical evaluation of the novel, orally bioavailable Selective Inhibitor of Nuclear Export (SINE) KPT-335 in spontaneous canine cancer: results of a phase I study.
    London CA; Bernabe LF; Barnard S; Kisseberth WC; Borgatti A; Henson M; Wilson H; Jensen K; Ito D; Modiano JF; Bear MD; Pennell ML; Saint-Martin JR; McCauley D; Kauffman M; Shacham S
    PLoS One; 2014; 9(2):e87585. PubMed ID: 24503695
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase II study of the oral selective inhibitor of nuclear export (SINE) KPT-335 (verdinexor) in dogs with lymphoma.
    Sadowski AR; Gardner HL; Borgatti A; Wilson H; Vail DM; Lachowicz J; Manley C; Turner A; Klein MK; Waite A; Sahora A; London CA
    BMC Vet Res; 2018 Aug; 14(1):250. PubMed ID: 30143046
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biologic activity of the novel orally bioavailable selective inhibitor of nuclear export (SINE) KPT-335 against canine melanoma cell lines.
    Breit MN; Kisseberth WC; Bear MD; Landesman Y; Kashyap T; McCauley D; Kauffman MG; Shacham S; London CA
    BMC Vet Res; 2014 Jul; 10():160. PubMed ID: 25022346
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preclinical antitumor efficacy of selective exportin 1 inhibitors in glioblastoma.
    Green AL; Ramkissoon SH; McCauley D; Jones K; Perry JA; Hsu JH; Ramkissoon LA; Maire CL; Hubbell-Engler B; Knoff DS; Shacham S; Ligon KL; Kung AL
    Neuro Oncol; 2015 May; 17(5):697-707. PubMed ID: 25366336
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-tumor activity of selective inhibitor of nuclear export (SINE) compounds, is enhanced in non-Hodgkin lymphoma through combination with mTOR inhibitor and dexamethasone.
    Muqbil I; Aboukameel A; Elloul S; Carlson R; Senapedis W; Baloglu E; Kauffman M; Shacham S; Bhutani D; Zonder J; Azmi AS; Mohammad RM
    Cancer Lett; 2016 Dec; 383(2):309-317. PubMed ID: 27693556
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The selective inhibitor of nuclear export (SINE) verdinexor exhibits biologic activity against canine osteosarcoma cell lines.
    Breitbach JT; Louke DS; Tobin SJ; Watts MR; Davies AE; Fenger JM
    Vet Comp Oncol; 2021 Jun; 19(2):362-373. PubMed ID: 33438820
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anti-tumor activity of selective inhibitors of XPO1/CRM1-mediated nuclear export in diffuse malignant peritoneal mesothelioma: the role of survivin.
    De Cesare M; Cominetti D; Doldi V; Lopergolo A; Deraco M; Gandellini P; Friedlander S; Landesman Y; Kauffman MG; Shacham S; Pennati M; Zaffaroni N
    Oncotarget; 2015 May; 6(15):13119-32. PubMed ID: 25948791
    [TBL] [Abstract][Full Text] [Related]  

  • 8. KPT-330 inhibitor of XPO1-mediated nuclear export has anti-proliferative activity in hepatocellular carcinoma.
    Zheng Y; Gery S; Sun H; Shacham S; Kauffman M; Koeffler HP
    Cancer Chemother Pharmacol; 2014 Sep; 74(3):487-95. PubMed ID: 25030088
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A method for quantification of exportin-1 (XPO1) occupancy by Selective Inhibitor of Nuclear Export (SINE) compounds.
    Crochiere ML; Baloglu E; Klebanov B; Donovan S; Del Alamo D; Lee M; Kauffman M; Shacham S; Landesman Y
    Oncotarget; 2016 Jan; 7(2):1863-77. PubMed ID: 26654943
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro evaluation of Selective Inhibitors of Nuclear Export (SINE) drugs KPT-185 and KPT-335 against canine mammary carcinoma and transitional cell carcinoma tumor initiating cells.
    Grayton JE; Miller T; Wilson-Robles H
    Vet Comp Oncol; 2017 Dec; 15(4):1455-1467. PubMed ID: 28133930
    [No Abstract]   [Full Text] [Related]  

  • 11. A Nuclear Attack on Traumatic Brain Injury: Sequestration of Cell Death in the Nucleus.
    Tajiri N; De La Peña I; Acosta SA; Kaneko Y; Tamir S; Landesman Y; Carlson R; Shacham S; Borlongan CV
    CNS Neurosci Ther; 2016 Apr; 22(4):306-15. PubMed ID: 26842647
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preclinical activity of a novel CRM1 inhibitor in acute myeloid leukemia.
    Ranganathan P; Yu X; Na C; Santhanam R; Shacham S; Kauffman M; Walker A; Klisovic R; Blum W; Caligiuri M; Croce CM; Marcucci G; Garzon R
    Blood; 2012 Aug; 120(9):1765-73. PubMed ID: 22677130
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Selective inhibition of nuclear export with selinexor in patients with non-Hodgkin lymphoma.
    Kuruvilla J; Savona M; Baz R; Mau-Sorensen PM; Gabrail N; Garzon R; Stone R; Wang M; Savoie L; Martin P; Flinn I; Jacoby M; Unger TJ; Saint-Martin JR; Rashal T; Friedlander S; Carlson R; Kauffman M; Shacham S; Gutierrez M
    Blood; 2017 Jun; 129(24):3175-3183. PubMed ID: 28468797
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Selinexor in combination with topotecan in patients with advanced or metastatic solid tumors: Results of an open-label, single-center, multi-arm phase Ib study.
    Thein KZ; Piha-Paul SA; Tsimberidou A; Karp DD; Janku F; Zarifa A; Shah J; Milton DR; Bean S; McQuinn L; Gong J; Colen R; Carter BW; Subbiah V; Ogbonna DC; Pant S; Meric-Bernstam F; Naing A
    Invest New Drugs; 2021 Oct; 39(5):1357-1365. PubMed ID: 33909232
    [TBL] [Abstract][Full Text] [Related]  

  • 15. KPT-330 inhibitor of CRM1 (XPO1)-mediated nuclear export has selective anti-leukaemic activity in preclinical models of T-cell acute lymphoblastic leukaemia and acute myeloid leukaemia.
    Etchin J; Sanda T; Mansour MR; Kentsis A; Montero J; Le BT; Christie AL; McCauley D; Rodig SJ; Kauffman M; Shacham S; Stone R; Letai A; Kung AL; Thomas Look A
    Br J Haematol; 2013 Apr; 161(1):117-27. PubMed ID: 23373539
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-tumor efficacy of Selinexor (KPT-330) in gastric cancer is dependent on nuclear accumulation of p53 tumor suppressor.
    Subhash VV; Yeo MS; Wang L; Tan SH; Wong FY; Thuya WL; Tan WL; Peethala PC; Soe MY; Tan DSP; Padmanabhan N; Baloglu E; Shacham S; Tan P; Koeffler HP; Yong WP
    Sci Rep; 2018 Aug; 8(1):12248. PubMed ID: 30115935
    [TBL] [Abstract][Full Text] [Related]  

  • 17. XPO1/CRM1-selective inhibitors of nuclear export (SINE) reduce tumor spreading and improve overall survival in preclinical models of prostate cancer (PCa).
    Gravina GL; Tortoreto M; Mancini A; Addis A; Di Cesare E; Lenzi A; Landesman Y; McCauley D; Kauffman M; Shacham S; Zaffaroni N; Festuccia C
    J Hematol Oncol; 2014 Oct; 7():46. PubMed ID: 25284315
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Deciphering mechanisms of drug sensitivity and resistance to Selective Inhibitor of Nuclear Export (SINE) compounds.
    Crochiere M; Kashyap T; Kalid O; Shechter S; Klebanov B; Senapedis W; Saint-Martin JR; Landesman Y
    BMC Cancer; 2015 Nov; 15():910. PubMed ID: 26573568
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Second-Generation Exportin-1 Inhibitor KPT-8602 Demonstrates Potent Activity against Acute Lymphoblastic Leukemia.
    Vercruysse T; De Bie J; Neggers JE; Jacquemyn M; Vanstreels E; Schmid-Burgk JL; Hornung V; Baloglu E; Landesman Y; Senapedis W; Shacham S; Dagklis A; Cools J; Daelemans D
    Clin Cancer Res; 2017 May; 23(10):2528-2541. PubMed ID: 27780859
    [No Abstract]   [Full Text] [Related]  

  • 20. First-in-Class, First-in-Human Phase I Study of Selinexor, a Selective Inhibitor of Nuclear Export, in Patients With Advanced Solid Tumors.
    Abdul Razak AR; Mau-Soerensen M; Gabrail NY; Gerecitano JF; Shields AF; Unger TJ; Saint-Martin JR; Carlson R; Landesman Y; McCauley D; Rashal T; Lassen U; Kim R; Stayner LA; Mirza MR; Kauffman M; Shacham S; Mahipal A
    J Clin Oncol; 2016 Dec; 34(34):4142-4150. PubMed ID: 26926685
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.